摘要
目的:了解临床上病毒性心肌炎(VMC)患者的用药现状。方法:抽取某"三甲"医院2008-2011年VMC出院患者病历85份,设计调查表,摘录其治疗信息,对其用药情况进行统计、分析。结果:该病好发于青壮年(78.8%)和婴幼儿(12.9%),有67.1%的患者在发病前1～3周有感冒受凉史或上呼吸道感染史。以抗感染(50.6%)、保护心肌(100%)、免疫调节(57.6%)、中药治疗(63.5%)及对并发症的对症支持治疗为主要治疗方案;治愈率为1.2%,好转率达91.8%,死亡率为5.9%。结论:治疗VMC应根据患者的具体情况进行个体化给药,并在治疗过程中注意中西医结合,方能达到治疗的最佳效果。
OBJECTIVE： To understand the status quo of drug used for viral myocarditis in the clinic. METHODS： 85 dis- charge cases of viral myocarditis were collected from a grade three class A hospital during 2008- 2011. The investigation report was designed to extract the patient information. The utilization of drugs was analyzed statistically. RESULTS： The disease was more likely to occur in young adults （78.8%） and babies （12.9%）, 68% of patients used to have a cold or upper respiratory tract infection 1 to 3 weeks ago. The main therapeutic scheme included： anti-infectious （50.6%）, nutrition myocardial （100%）, immu- nosuppressive treatment （57.6%）, traditional Chinese medicine treatment （63.5%） and symptomatic supporting treatment. The cura- tive rate, improvement rate and mortality rate were 1.2%, 91.8% and 5.9%. CONCLUSION： Individual drug scheme should be provided for the treatment of viral myocarditis according to the specific situation of patients, and we should pay attention to the combination of traditional Chinese medicine with western medicine so as to achieve a better treatment outcome.
出处
《中国药房》
CAS
CSCD
2012年第42期3954-3957,共4页
China Pharmacy
关键词
病毒性心肌炎
药物治疗
用药分析
Viral myocarditis
Drug therapy
Analysis of drug use
